Periodic Reporting for period 1 - ERA PerMed (ERA-Net Cofund in Personalised Medicine)
Reporting period: 2017-12-01 to 2018-11-30
Horizon 2020 defined Personalised Medicine as "a medical model using characterization of individuals’ phenotypes and genotypes (e.g. molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention". Personalised Medicine (PM) represents a paradigm shift away from a ‘one size fits all’ approach to the treatment and care of patients with a particular condition, to one which uses emergent approaches in areas such as diagnostic tests, functional genomic technologies, molecular pathways, data analytics and real time monitoring of conditions to better manage patients’ health and to target therapies to achieve the best outcomes in the management of a patient’s disease or predisposition to disease. At the same time, one key objective of personalised medicine is to make health systems more sustainable by reducing costs.
In the face of this potential huge leap forward, the fact that personalised medicine lacks the cooperation and coordination needed to reorganise the still very fragmented field is a severe drawback to its development. In this regard, major efforts must be directed towards creating the conditions for coordinating and aligning relevant stakeholders (public institutions, governments, industry, civil society, patient organisations) in personalised medicine action across Europe and beyond.
ERA PerMed serves as a funding vehicle of topics identified in the Strategic Research and Innovation Agenda (SRIA) in Personalised Medicine and the Action Plan of ICPerMed.
ERA PerMed coordinates R&I efforts of the participating partners (funding agencies from EU, associate countries to H2020 and third countries). The main objective is planning, implementing, monitoring and disseminate up to four joint transnational calls (JTCs) tackling the value change in full to fund multidisciplinary transnational research projects covering each at least three slots of the value chain regarding Personalised Medicine.
The ERA PerMed consortium is open to enlargement for the planned JTCs. According to funding scheme’s rules, ERA PerMed partners commit themselves to implement one call with top-up co-funding from the EC, and include funded project monitoring. Additionally, up to three non-cofunded calls will be carried, in order to broaden the scope of action of the efforts made by the EC and funding organizations to foster the Personalised Medicine Research Community and to be able to take into account recent changes within the landscape of personalised medicine, e.g. new developments of emerging technologies and societal challenges, which reinforces and amplifies the expected impact of ERA PerMed funding activity.
In the face of this potential huge leap forward, the fact that personalised medicine lacks the cooperation and coordination needed to reorganise the still very fragmented field is a severe drawback to its development. In this regard, major efforts must be directed towards creating the conditions for coordinating and aligning relevant stakeholders (public institutions, governments, industry, civil society, patient organisations) in personalised medicine action across Europe and beyond.
ERA PerMed serves as a funding vehicle of topics identified in the Strategic Research and Innovation Agenda (SRIA) in Personalised Medicine and the Action Plan of ICPerMed.
ERA PerMed coordinates R&I efforts of the participating partners (funding agencies from EU, associate countries to H2020 and third countries). The main objective is planning, implementing, monitoring and disseminate up to four joint transnational calls (JTCs) tackling the value change in full to fund multidisciplinary transnational research projects covering each at least three slots of the value chain regarding Personalised Medicine.
The ERA PerMed consortium is open to enlargement for the planned JTCs. According to funding scheme’s rules, ERA PerMed partners commit themselves to implement one call with top-up co-funding from the EC, and include funded project monitoring. Additionally, up to three non-cofunded calls will be carried, in order to broaden the scope of action of the efforts made by the EC and funding organizations to foster the Personalised Medicine Research Community and to be able to take into account recent changes within the landscape of personalised medicine, e.g. new developments of emerging technologies and societal challenges, which reinforces and amplifies the expected impact of ERA PerMed funding activity.
ERA PerMed officially started on December 1st 2017 with the participation of 32 funding institutions. The first Transnational Joint Call was launched in February 2018 and as a result, 25 scientific projects have been funded (28.271.516 €).
Next 2019, we are going to launch the second JTC in which ERA PerMed fosters research and innovation activities that build close linkages between basic biomedical research, clinical research, physical sciences and bioengineering, bioinformatics and biostatistics, epidemiology, socio-economic research, as well as research on the integration of PM into clinical practice and on ethical, legal and social implications across the participating countries and beyond.
The ultimate goal and expected outcome of ERA PerMed is to strongly contribute to the building of a more effective European Research Area by facilitating and coordinating regional and national European research funding programmes on Personalized Medicine. ERA PerMed wants to contribute to its overarching goal which is to put the citizen at the centre of healthcare and to prevent diseases instead of only treating them, reducing the cost of healthcare and creating a virtuous circle for health policy.
The overall expected impact of ERA PerMed is a thorough, lasting and forward-looking alignment of current European (and Canadian) funding organisations with the goals of creating synergies and coherence in personalised at national and regional level. Personalised medicine is an interdisciplinary field that will drive the health research and innovation agenda for years to come.
For more information, please visit: http://www.erapermed.eu/
The ultimate goal and expected outcome of ERA PerMed is to strongly contribute to the building of a more effective European Research Area by facilitating and coordinating regional and national European research funding programmes on Personalized Medicine. ERA PerMed wants to contribute to its overarching goal which is to put the citizen at the centre of healthcare and to prevent diseases instead of only treating them, reducing the cost of healthcare and creating a virtuous circle for health policy.
The overall expected impact of ERA PerMed is a thorough, lasting and forward-looking alignment of current European (and Canadian) funding organisations with the goals of creating synergies and coherence in personalised at national and regional level. Personalised medicine is an interdisciplinary field that will drive the health research and innovation agenda for years to come.
For more information, please visit: http://www.erapermed.eu/